



Neoadjuvant Chemotherapy for Breast Cancer

Guest Editor:

Dr. Shin-Cheh Chen

Breast Surgery Division,
Department of General Surgery,
Chang Gung Memorial Hospital
at Linkou, Chang Gung
University, Taoyuan 333, Taiwan

Deadline for manuscript
submissions:

30 June 2024

Message from the Guest Editor

Dear Colleagues,

One of the scientific backgrounds of neoadjuvant chemotherapy is the hypothesis that earlier treatment with the eradication of subclinical micrometastasis will improve survival. The pioneering clinical trials by the I-SPY2 working group have successfully identified the therapeutic agents through pCR improvement and established the "response predictor subtype".

Still, there are a lot of unresolved issues regarding the neoadjuvant chemotherapy of breast cancer, such as the predictor of pCR, the best sequence of the therapeutic regimen, the effective treatment of non-pCR patients, the role of conventional chemotherapy in terms of immunological effect, de-escalation after pCR, and escalation therapy for non-pCR. To breast surgeons, the extent of breast surgery and the efficacy of sentinel node biopsy after NAC and the best strategy for axillary management after nodal pCR are still controversial.

Through the Special Issue titled "Neoadjuvant Chemotherapy for Breast Cancer" of *Cancers*, all experts in this field are invited to contribute and submit their papers in an attempt to resolve the above issues.

Dr. Shin-Cheh Chen
Guest Editor





cancers



an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic
Oncology and Reproductive
Medicine, The University of Texas
MD Anderson Cancer Center,
Houston, TX 77030, USA

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank: JCR - Q2 (*Oncology*) / CiteScore - Q1 (*Oncology*)

Contact Us

Cancers Editorial Office
MDPI, St. Alban-Anlage 66
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/cancers
cancers@mdpi.com
X@Cancers_MDPI